PLAU, plasminogen activator, urokinase, 5328

N. diseases: 439; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE The urokinase-type plasminogen activator receptor (uPAR) is overexpressed in several cancers including glioblastoma (GBM) and is an established biomarker for metastatic potential. 28316028 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. 21896743 2011
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 GeneticVariation disease BEFREE In summary, these results suggest that c-Src, mitogen-activated protein kinase, and a composite activator protein 1 on the uPA promoter are responsible for EGF-induced uPA expression and GBM invasion. 20467333 2010
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 AlteredExpression disease BEFREE Glioblastoma multiforme (GM), the most frequent primary malignant brain tumor, is highly invasive due to the expression of proteases, including urokinase-type plasminogen activator (uPA). 20606645 2010
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 AlteredExpression disease BEFREE Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness. 18819934 2008
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 AlteredExpression disease LHGDN Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. 18355442 2008
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 AlteredExpression disease BEFREE A correlation between overexpression of urokinase-type plasminogen activator receptor (uPAR) and glioblastoma invasion has also been established. 17273768 2007
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 AlteredExpression disease LHGDN In xenograft glioblastoma mouse model and in vitro transmembrane invasion assay, LRP-deficient cells, which secreted high levels of urokinase-type plasminogen activator (uPA), invaded extensively the surrounding normal brain tissue, whereas the LRP-overexpressing and uPA-deficient cells did not invade into the surrounding normal brain. siRNA, targeted against uPA in LRP-deficient clones, attenuated their invasive potential. 17974965 2007
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE A bispecific immunotoxin (IT) called DTAT13 was synthesized in order to target simultaneously the urokinase-type plasminogen activator receptor (uPAR)-expressing tumor neovasculature and IL-13 receptor expressing glioblastoma cells with the goal of intratumoral administration for brain tumors. 15047912 2004
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE Stably transfecting human glioblastoma cells with antisense uPA decreased the amount of cell-bound uPA and disrupted actin cytoskeleton formation and cell migration. 12545160 2003
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE We assessed how expression of an amino-terminal fragment (ATF) of uPA that contains binding site to uPAR affects the invasiveness of SNB19 human glioblastoma cells. 12420219 2002
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE We reported previously that the production of urokinase-type plasminogen activator receptor (uPAR) protein is greater in high-grade glioblastomas than in low-grade gliomas. 11234878 2001
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE To investigate the role of uPA in the invasive process of brain tumors, we stably transfected a human glioblastoma cell line SNB19 with a vector capable of expressing an antisense transcript complementary to the 1020 bases at the 3' end of the uPA cDNA. 11489835 2001
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 AlteredExpression disease BEFREE We further studied the activation and inhibition of uPA promoter by co-expression of a transactivation domain lacking c-jun: a dominant negative ERK1 and ERK2 mutant and a dominant negative c-raf in glioblastoma cell line showed repressed uPA promoter activity compared with the effect of the empty expression vector. 11115541 2001
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE Levels of uPA mRNA expression in tumor tissues with recurrence during 18 postoperative months and a survival period less than 3 years, were significantly higher than counterparts (P < 0.01). uPA mRNA expression was strongly correlated with the microvessel quantity (MVQ) in gliomas (r = 0.56, P < 0.01). uPA protein was mainly distributed in tumor cells and endothelial cells of glioblastomas and anaplastic astrocytomas. 11776074 2000
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 AlteredExpression disease BEFREE Downregulation of urokinase-type plasminogen activator receptor (uPAR) induces caspase-mediated cell death in human glioblastoma cells. 11688967 2000
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE The distribution of uPA protein in the immunoreactivity was mainly in tumor cells and microvascular endothelial cells of glioblastomas and anaplastic astrocytomas, localizing at cytoplasms, especially near sites of vascular proliferation and at the leading edges of tumors. 10914816 2000
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE The distribution of uPA protein immunoreactivity was mainly in tumour cells and microvascular endothelial cells of glioblastomas and anaplastic astrocytomas, localising in the cytoplasm, especially at sites of vascular proliferation and at the leading edges of tumours. 10844794 2000
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 AlteredExpression disease BEFREE Glioblastomas express more urokinase-type plasminogen activator receptor (uPAR) than do low-grade gliomas and normal brain tissue. 10853019 2000
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE Thus uPAR appears in this model to be essential for tumorigenicity and invasion of glioblastomas in vivo. 9219733 1997
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 AlteredExpression disease BEFREE Furthermore, adherent human U-251MG glioblastoma cells in vitro expressed u-PAR and u-PA proteins, which localized to sites of integrin alpha nu beta 3 cell-matrix contacts. 7747809 1995
CUI: C0017636
Disease: Glioblastoma
Glioblastoma
0.100 Biomarker disease BEFREE Immunocytochemical staining for uPA showed strong immunoreactivity in the tumor cells and vasculature of glioblastomas and anaplastic astrocytomas but undetectable or very low immunoreactivity for uPA in low-grade gliomas and normal brain tissues. uPA mRNA was located in astrocytoma and endothelial cells and was heterogeneously distributed within glioblastoma, with preferential localization near vascular proliferation and at the leading edge of the tumor. uPA expression was dramatically higher in highly malignant astrocytomas, especially glioblastomas, and was correlated with malignant progression of astrocytomas. 8033079 1994